Bevacizumab, a humanized anti-VEGF monoclonal antibody, suppresses angiogenesis and tumor development in HCC [68], showing ORRs of 13% [69] and 14% [70] in single-agent phase II trials for advanced HCC. Here, VEGFA is linked to neoplasm.